JP7065775B2 - 化合物及びそれらの治療用途 - Google Patents

化合物及びそれらの治療用途 Download PDF

Info

Publication number
JP7065775B2
JP7065775B2 JP2018537732A JP2018537732A JP7065775B2 JP 7065775 B2 JP7065775 B2 JP 7065775B2 JP 2018537732 A JP2018537732 A JP 2018537732A JP 2018537732 A JP2018537732 A JP 2018537732A JP 7065775 B2 JP7065775 B2 JP 7065775B2
Authority
JP
Japan
Prior art keywords
nhco
compound
formula
preparation
conh
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018537732A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018531287A (ja
JP2018531287A5 (enExample
JP2018531287A6 (ja
Inventor
ピックフォード クリストファー
ワトソン クリスティン
グロソップ メラニー
Original Assignee
センタウリ セラピューティクス リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by センタウリ セラピューティクス リミテッド filed Critical センタウリ セラピューティクス リミテッド
Publication of JP2018531287A publication Critical patent/JP2018531287A/ja
Publication of JP2018531287A6 publication Critical patent/JP2018531287A6/ja
Publication of JP2018531287A5 publication Critical patent/JP2018531287A5/ja
Application granted granted Critical
Publication of JP7065775B2 publication Critical patent/JP7065775B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Air Filters, Heat-Exchange Apparatuses, And Housings Of Air-Conditioning Units (AREA)
  • Central Air Conditioning (AREA)
JP2018537732A 2015-10-08 2016-10-07 化合物及びそれらの治療用途 Active JP7065775B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1517859.3 2015-10-08
GBGB1517859.3A GB201517859D0 (en) 2015-10-08 2015-10-08 Novel compounds and therapeutic uses thereof
PCT/GB2016/053134 WO2017060729A1 (en) 2015-10-08 2016-10-07 Compounds and therapeutic uses thereof

Publications (4)

Publication Number Publication Date
JP2018531287A JP2018531287A (ja) 2018-10-25
JP2018531287A6 JP2018531287A6 (ja) 2018-12-13
JP2018531287A5 JP2018531287A5 (enExample) 2019-11-21
JP7065775B2 true JP7065775B2 (ja) 2022-05-12

Family

ID=55130801

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018537732A Active JP7065775B2 (ja) 2015-10-08 2016-10-07 化合物及びそれらの治療用途

Country Status (10)

Country Link
US (2) US10953100B2 (enExample)
EP (1) EP3359201A1 (enExample)
JP (1) JP7065775B2 (enExample)
CN (1) CN108472381B (enExample)
AU (1) AU2016335365B2 (enExample)
CA (1) CA3001084A1 (enExample)
GB (1) GB201517859D0 (enExample)
IL (1) IL258511B (enExample)
WO (2) WO2017060728A1 (enExample)
ZA (1) ZA201802256B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201707076D0 (en) * 2017-05-04 2017-06-21 Centauri Therapeutics Ltd Novel compounds and therapeutic uses thereof
JP7185622B2 (ja) * 2016-09-13 2022-12-07 センタウリ セラピューティクス リミテッド 新規化合物及びその治療上の使用
GB201705686D0 (en) * 2017-04-07 2017-05-24 Centauri Therapeutics Ltd Novel compounds and therapeutic uses thereof
GB201705684D0 (en) * 2017-04-07 2017-05-24 Centauri Therapeutics Ltd Novel compounds and therapeutic uses thereof
GB201707079D0 (en) * 2017-05-04 2017-06-21 Centauri Therapeutics Ltd Novel compounds and therapeutics uses thereof
GB201816554D0 (en) 2018-10-10 2018-11-28 Centauri Therapeutics Ltd Novel compounds and therapeutic uses thereof
CN111748089B (zh) * 2019-03-28 2023-07-18 成都先导药物开发股份有限公司 一种生物素标记化合物以及确定化合物结合靶标蛋白的方法
CN116535449B (zh) * 2023-03-22 2025-09-16 华东理工大学 一种糖基没食子酸类衍生物及其制备方法与在制备乳腺癌靶向诊疗材料中的应用
GB202406865D0 (en) 2024-05-15 2024-06-26 Centauri Therapeutics Ltd Novel compounds and therapeutics uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005535723A (ja) 2002-08-20 2005-11-24 バイオティ セラピィーズ コープ 腫瘍特異的オリゴ糖エピトープおよびその用途
JP2007527419A (ja) 2004-01-09 2007-09-27 キャリー ビー． マリス、 化学的にプログラム可能な免疫
JP2012526130A (ja) 2009-05-05 2012-10-25 アルテルムネ テクフノロジエス，エルエルシー 化学的にプログラム可能な免疫

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6172045B1 (en) 1994-12-07 2001-01-09 Neorx Corporation Cluster clearing agents
JP4430344B2 (ja) * 2002-09-09 2010-03-10 独立行政法人科学技術振興機構 多岐用途型リンカー化合物及びリガンド、並びにそれらの製造方法
WO2005014008A2 (en) * 2003-07-17 2005-02-17 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Treatment of disorders associated with natural killer t cells
CN101360728A (zh) * 2005-10-25 2009-02-04 艾吉拉医疗股份有限公司 Iap bir结构域结合化合物
US7998486B2 (en) * 2006-10-25 2011-08-16 Newlink Genetics Corporation Enhanced immunogenicity of tumor associated antigens by addition of alphaGal epitopes
US9636419B2 (en) * 2013-10-11 2017-05-02 The Universit of Kansas Targeting multiple receptors on a cell surface for specific cell targeting
GB201411150D0 (en) 2014-06-23 2014-08-06 Altermune Technologies Llc Novel aptamers and therapeutic uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005535723A (ja) 2002-08-20 2005-11-24 バイオティ セラピィーズ コープ 腫瘍特異的オリゴ糖エピトープおよびその用途
JP2007527419A (ja) 2004-01-09 2007-09-27 キャリー ビー． マリス、 化学的にプログラム可能な免疫
JP2012526130A (ja) 2009-05-05 2012-10-25 アルテルムネ テクフノロジエス，エルエルシー 化学的にプログラム可能な免疫

Also Published As

Publication number Publication date
NZ741118A (en) 2024-07-26
US10953100B2 (en) 2021-03-23
IL258511A (en) 2018-06-28
US20210369850A1 (en) 2021-12-02
CN108472381A (zh) 2018-08-31
IL258511B (en) 2021-10-31
AU2016335365B2 (en) 2021-12-09
JP2018531287A (ja) 2018-10-25
GB201517859D0 (en) 2015-11-25
AU2016335365A1 (en) 2018-04-26
US20180280521A1 (en) 2018-10-04
EP3359201A1 (en) 2018-08-15
CN108472381B (zh) 2023-06-06
WO2017060729A1 (en) 2017-04-13
CA3001084A1 (en) 2017-04-13
ZA201802256B (en) 2019-01-30
WO2017060728A1 (en) 2017-04-13

Similar Documents

Publication Publication Date Title
JP7065775B2 (ja) 化合物及びそれらの治療用途
JP2018531287A6 (ja) 化合物及びそれらの治療用途
US11787766B2 (en) Compound having PD-L1 inhibitory activity, preparation method therefor and use thereof
JP6378182B2 (ja) 過剰増殖性│疾患の処置のためのセリン／スレオニンキナーゼ阻害剤
WO2015158310A1 (zh) 一种酪氨酸激酶抑制剂及其用途
TW201843154A (zh) 抗微生物化合物及其製造與使用方法
US20250241979A1 (en) Novel compounds and therapeutics uses thereof
CN114585621B (zh) 咪唑并喹啉胺衍生物、及其药物组合物和应用
CN108863850A (zh) 联芳基类化合物及其制备方法和用途
JP2022184922A (ja) 新規化合物及びその治療上の使用
JP2024150440A (ja) 化合物及びその治療的使用
WO2022253152A1 (zh) 7-硝基-8-羟基喹啉衍生物、其制备方法及其医药用途
US20250282766A1 (en) PTPN2/PTP1B Degrader and Therapeutic Method Thereof
US20220162262A1 (en) Novel compounds and therapeutic uses thereof
EP3606558B1 (en) Novel compounds and therapeutic uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180718

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191004

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191004

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201124

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210326

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210817

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211116

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220329

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220426

R150 Certificate of patent or registration of utility model

Ref document number: 7065775

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250